Chemical Restraint: When medication Is the Harm | Episode 90

The medication harm series closes with chemical restraint: a drug given not to treat a condition but to control behavior for staff convenience, prohibited by federal nursing home regulation, and the medication harm most often missed because it looks like treatment. Michelle Carroll is careful with the distinction. Antipsychotics and sedatives have legitimate uses. The question is whether this drug, for this resident, was prescribed for a diagnosed condition, at the lowest effective dose, with a reduction plan, with behavior and function monitored. She puts the Regulatory and Compliance Overlay first for this episode and walks through what the regulation requires and what each requirement should leave in the record: a diagnosis rather than a symptom, a behavior monitoring log, gradual dose reduction attempts, a 14-day review on PRN orders, and a physician response to every pharmacist flag. She covers what to look for beyond the regulation: the single triggering incident that started the drug, PRN timing plotted against the shift schedule, the MDS trajectory showing the resident's decline alongside the drug's dose increases, and the federal black box warning on antipsychotic use in elderly patients with dementia. A composite case follows a woman with moderate dementia started on an antipsychotic for "agitation" after one incident in the shower, whose behavior log showed nothing for five months, whose pharmacist flagged the drug three times with no response, and who went from walking and eating to bedbound and fourteen pounds lighter before dying of aspiration pneumonia. The episode closes with the defense arguments, a discovery checklist, and the thread that runs through all five episodes: the medication record looked orderly in every setting. The failures were in what surrounded it. Lexcura Clinical Insights is hosted by Michelle Carroll, Founder and Chief Clinical Strategist of Lexcura Summit. Medical-Legal Analysis for attorneys. lexcurasummit.com